Cargando…

Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4

To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo, and to investigate its related molecular pathway in vitro, an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)-β2 in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Xiang-Yuan, Chen, Ya-Ying, Liu, Wen-Ting, Cong, Lin, Zhang, Jin-Ling, Zhang, Yang, Zhang, Yu-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015665/
https://www.ncbi.nlm.nih.gov/pubmed/35417030
http://dx.doi.org/10.3892/ijmm.2022.5132
_version_ 1784688362050813952
author Song, Xiang-Yuan
Chen, Ya-Ying
Liu, Wen-Ting
Cong, Lin
Zhang, Jin-Ling
Zhang, Yang
Zhang, Yu-Yan
author_facet Song, Xiang-Yuan
Chen, Ya-Ying
Liu, Wen-Ting
Cong, Lin
Zhang, Jin-Ling
Zhang, Yang
Zhang, Yu-Yan
author_sort Song, Xiang-Yuan
collection PubMed
description To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo, and to investigate its related molecular pathway in vitro, an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)-β2 in the right eye of BALB/cJ mice, while the left was treated with an empty control adenovirus. To determine its anti-intraocular hypertension role, these induced hyper-IOP mice were gavaged with atorvastatin (20 mg/kg/day). Furthermore, extracellular matrix (ECM) factors were examined in the primary human trabecular meshwork (HTM) cells followed atorvastatin (0~200 µM) treatment in vitro. Whole genome microarray was employed to identify potential therapeutic target molecules associated with ECM regulation. Unilateral murine ocular hypertension was induced, via intravitreal injection of the adenoviral vector carrying the human TGF-β2 gene (Ad.hTGF-β2(226/228)), raising IOP from 12±1.6 to 32.3±0.7 mmHg (n=6, P<0.05) at day 15, which plateaued from day 15 to 30. Atorvastatin administration from day 15 to 30 decreased IOP from 32.3±0.7 to 15.4±1.1 mmHg (n=6, P<0.05) at day 30. Additionally, atorvastatin administration changed the morphology of cultured HTM cells from an elongated and adherent morphology into rounded, less elongated and less adherent cells, accompanied with suppressed expression of ECM. Gene Ontology and Genome analysis revealed that FGD4 (FYVE, RhoGEF and PH domain containing 4) might be a key factor contributing to these changes. Our data demonstrated that atorvastatin reduced TGF-β2-induced ocular hypertension in vivo, perhaps via modifying cellular structure and decreasing ECM, using the FGD4 signaling pathway, as demonstrated in HTM cells. Our findings provide some useful information for the management of glaucoma, with statin therapy revealing a potential novel therapeutic pathway for glaucoma treatment.
format Online
Article
Text
id pubmed-9015665
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-90156652022-04-26 Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4 Song, Xiang-Yuan Chen, Ya-Ying Liu, Wen-Ting Cong, Lin Zhang, Jin-Ling Zhang, Yang Zhang, Yu-Yan Int J Mol Med Articles To explore the role of atorvastatin in regulating intraocular pressure (IOP) in glaucoma in vivo, and to investigate its related molecular pathway in vitro, an ocular hypertension model was generated by intravitreal injection of an adenoviral vector encoding transforming growth factor (TGF)-β2 in the right eye of BALB/cJ mice, while the left was treated with an empty control adenovirus. To determine its anti-intraocular hypertension role, these induced hyper-IOP mice were gavaged with atorvastatin (20 mg/kg/day). Furthermore, extracellular matrix (ECM) factors were examined in the primary human trabecular meshwork (HTM) cells followed atorvastatin (0~200 µM) treatment in vitro. Whole genome microarray was employed to identify potential therapeutic target molecules associated with ECM regulation. Unilateral murine ocular hypertension was induced, via intravitreal injection of the adenoviral vector carrying the human TGF-β2 gene (Ad.hTGF-β2(226/228)), raising IOP from 12±1.6 to 32.3±0.7 mmHg (n=6, P<0.05) at day 15, which plateaued from day 15 to 30. Atorvastatin administration from day 15 to 30 decreased IOP from 32.3±0.7 to 15.4±1.1 mmHg (n=6, P<0.05) at day 30. Additionally, atorvastatin administration changed the morphology of cultured HTM cells from an elongated and adherent morphology into rounded, less elongated and less adherent cells, accompanied with suppressed expression of ECM. Gene Ontology and Genome analysis revealed that FGD4 (FYVE, RhoGEF and PH domain containing 4) might be a key factor contributing to these changes. Our data demonstrated that atorvastatin reduced TGF-β2-induced ocular hypertension in vivo, perhaps via modifying cellular structure and decreasing ECM, using the FGD4 signaling pathway, as demonstrated in HTM cells. Our findings provide some useful information for the management of glaucoma, with statin therapy revealing a potential novel therapeutic pathway for glaucoma treatment. D.A. Spandidos 2022-06 2022-04-13 /pmc/articles/PMC9015665/ /pubmed/35417030 http://dx.doi.org/10.3892/ijmm.2022.5132 Text en Copyright: © Song et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Song, Xiang-Yuan
Chen, Ya-Ying
Liu, Wen-Ting
Cong, Lin
Zhang, Jin-Ling
Zhang, Yang
Zhang, Yu-Yan
Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title_full Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title_fullStr Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title_full_unstemmed Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title_short Atorvastatin reduces IOP in ocular hypertension in vivo and suppresses ECM in trabecular meshwork perhaps via FGD4
title_sort atorvastatin reduces iop in ocular hypertension in vivo and suppresses ecm in trabecular meshwork perhaps via fgd4
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015665/
https://www.ncbi.nlm.nih.gov/pubmed/35417030
http://dx.doi.org/10.3892/ijmm.2022.5132
work_keys_str_mv AT songxiangyuan atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT chenyaying atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT liuwenting atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT conglin atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT zhangjinling atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT zhangyang atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4
AT zhangyuyan atorvastatinreducesiopinocularhypertensioninvivoandsuppressesecmintrabecularmeshworkperhapsviafgd4